TARO - TARO PHARM INDUS ()

TAROのニュース

   Taro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26M  2022/05/27 06:10:18 Seeking Alpha
Taro Pharmaceutical press release (TARO): Q4 GAAP EPS of $0.73.Revenue of $143.26M (-3.4% Y/Y).
   Taro Provides Results for the Year Ended March 31, 2022  2022/05/26 23:00:00 Wallstreet:Online
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The quarter ended March 31, 2022, includes one month’s results from the February 28th acquisition of Alchemee. Net sales of $143.3 million
   Taro Pharmaceutical Industries Shares Fall 0.5% Below Previous 52-Week Low - Market Mover  2022/05/26 00:00:00 Kwhen Finance
Taro Pharmaceutical Industries (TARO) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 26.9% year-to-date, down 47.9% over the past 12 months, and down 60.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.8%, and the S&P 500 rose 1.4%. Trading Activity Trading volume this week was 105.3% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -445.6% The company's stock price performance over the past 12 months lags the peer average by -421.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Taro Pharmaceutical Q1 2022 Earnings Preview  2022/05/25 21:35:56 Seeking Alpha
Taro Pharmaceutical (TARO) is scheduled to announce Q1 earnings results on Thursday, May 26th, after market close.The consensus EPS Estimate is $0.88 (+8.6% Y/Y) and the consensus…
   Sensex Zooms 1,223 Points, Nifty Settles Above 16,300; Asian Paints, M&M and Bajaj Finance Surge 5%  2022/03/09 10:30:00 EquityMaster
Posted by Equitymaster Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note. Benchmark indices added to yesterday''s gains following a clawback in European markets and US futures as smart investors saw value in the current market valuations. The Sensex reclaimed 54,600 levels while the Nifty clawed back to 16,300 levels led by media, realty, and auto stocks. The sharp rally comes on hopes of de-escalation of the Russia-Ukraine conflict after the Ukrainian President Zelenskyy indicated that the country was no longer interest in NATO membership, the main reason behind the war. At the closing bell, the BSE Sensex stood higher by 1,223 points (up 2.3%). Meanwhile, the NSE Nifty closed higher by 332 points (up 2.1%). Asian Paints and Reliance Industries were among the top gainers today . Shree Cement and ONGC, on the other hand, were among the top losers today . The SGX Nifty was trading at 16,350, up by 408 points, at the time of writing.
   Taro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26M  2022/05/27 06:10:18 Seeking Alpha
Taro Pharmaceutical press release (TARO): Q4 GAAP EPS of $0.73.Revenue of $143.26M (-3.4% Y/Y).
   Taro Provides Results for the Year Ended March 31, 2022  2022/05/26 23:00:00 Wallstreet:Online
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The quarter ended March 31, 2022, includes one month’s results from the February 28th acquisition of Alchemee. Net sales of $143.3 million
   Taro Pharmaceutical Industries Shares Fall 0.5% Below Previous 52-Week Low - Market Mover  2022/05/26 00:00:00 Kwhen Finance
Taro Pharmaceutical Industries (TARO) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 26.9% year-to-date, down 47.9% over the past 12 months, and down 60.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.8%, and the S&P 500 rose 1.4%. Trading Activity Trading volume this week was 105.3% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -445.6% The company's stock price performance over the past 12 months lags the peer average by -421.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Taro Pharmaceutical Q1 2022 Earnings Preview  2022/05/25 21:35:56 Seeking Alpha
Taro Pharmaceutical (TARO) is scheduled to announce Q1 earnings results on Thursday, May 26th, after market close.The consensus EPS Estimate is $0.88 (+8.6% Y/Y) and the consensus…
   Sensex Zooms 1,223 Points, Nifty Settles Above 16,300; Asian Paints, M&M and Bajaj Finance Surge 5%  2022/03/09 10:30:00 EquityMaster
Posted by Equitymaster Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note. Benchmark indices added to yesterday''s gains following a clawback in European markets and US futures as smart investors saw value in the current market valuations. The Sensex reclaimed 54,600 levels while the Nifty clawed back to 16,300 levels led by media, realty, and auto stocks. The sharp rally comes on hopes of de-escalation of the Russia-Ukraine conflict after the Ukrainian President Zelenskyy indicated that the country was no longer interest in NATO membership, the main reason behind the war. At the closing bell, the BSE Sensex stood higher by 1,223 points (up 2.3%). Meanwhile, the NSE Nifty closed higher by 332 points (up 2.1%). Asian Paints and Reliance Industries were among the top gainers today . Shree Cement and ONGC, on the other hand, were among the top losers today . The SGX Nifty was trading at 16,350, up by 408 points, at the time of writing.
   Aleor Dermaceuticals receives US FDA final approval for Nystatin and Triamcinolone Acetonide Ointment  2022/03/08 08:26:54 Express Pharma
The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD) Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 U/g/0.1 per cent, of Taro Pharmaceuticals The post Aleor Dermaceuticals receives US FDA final approval for Nystatin and Triamcinolone Acetonide Ointment appeared first on Express Pharma .
   Taro Pharmaceutical to acquire Alchemee from Galderma  2022/02/22 14:45:24 Seeking Alpha
Taro Pharmaceutical Industries (TARO) will acquire Alchemee from Galderma.The deal includes Alchemees business as well as its flagship acne care brand Proactiv.
   Taro Pharmaceutical Industries Shares Close in on 52-Week Low - Market Mover  2022/02/07 23:43:31 Kwhen Finance
Taro Pharmaceutical Industries (TARO) shares closed today at 1.5% above its 52 week low of $43.29, giving the company a market cap of $1B. The stock is currently down 11.7% year-to-date, down 41.3% over the past 12 months, and down 52.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Trading volume this week was 17.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 26640.3% The company's stock price performance over the past 12 months lags the peer average by -431.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Taro Pharmaceutical Q3 2022 Earnings Preview  2022/01/26 22:35:38 Seeking Alpha
Taro Pharmaceutical (NYSE:TARO) is scheduled to announce Q3 earnings results on Thursday, January 27th, after market close.The consensus EPS Estimate is $0.91 (+37.9% Y/Y) and the…
   Taro Pharmaceutical Industries Shares Near 52-Week Low - Market Mover  2022/01/04 13:20:28 Kwhen Finance
Taro Pharmaceutical Industries (TARO) shares closed today at 1.4% above its 52 week low of $45.00, giving the company a market cap of $1B. The stock is currently down 9.0% year-to-date, down 37.9% over the past 12 months, and down 51.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 15.0% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -8230.7% The company's stock price performance over the past 12 months lags the peer average by -389.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

calendar